A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Pharmaceutical share prices fell last Monday, after US President Donald Trump vowed to reduce drug prices in the USA by as ...

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

As of Thursday, May 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 5.79%, which has investors questioning if ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

GlaxoSmithKline has an analyst consensus of Hold, with a price target consensus of p1,404.46. Based on GlaxoSmithKline’s latest earnings release for the quarter ending March 31, the company reported a ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...